BR112015011099A2 - Composições e métodos para o tratamento de diplasia ectodérmica - Google Patents

Composições e métodos para o tratamento de diplasia ectodérmica

Info

Publication number
BR112015011099A2
BR112015011099A2 BR112015011099A BR112015011099A BR112015011099A2 BR 112015011099 A2 BR112015011099 A2 BR 112015011099A2 BR 112015011099 A BR112015011099 A BR 112015011099A BR 112015011099 A BR112015011099 A BR 112015011099A BR 112015011099 A2 BR112015011099 A2 BR 112015011099A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
ectodermal
treatment
diplasia
Prior art date
Application number
BR112015011099A
Other languages
English (en)
Inventor
M Huttner Kenneth
Kirby Neil
Schneider Pascal
Gaide Olivier
Original Assignee
Edimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edimer Pharmaceuticals Inc filed Critical Edimer Pharmaceuticals Inc
Publication of BR112015011099A2 publication Critical patent/BR112015011099A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA O TRATAMENTO DE DISPLASIA ECTODÉRMICA. A invenção se refere a composições farmacêuticas e a métodos para o tratamento de displasias ectodérmicas através da administração de agonistas de EDA, em particular, EDI200. O uso das composições e métodos descritos proporciona a administração terapêutica e regimes de administração em pacientes humanos para corrigir ou alterar fenótipos anormais associados com distúrbios genéticas, em particular, XLHED.
BR112015011099A 2012-11-14 2013-11-13 Composições e métodos para o tratamento de diplasia ectodérmica BR112015011099A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726252P 2012-11-14 2012-11-14
US201361825227P 2013-05-20 2013-05-20
PCT/US2013/069799 WO2014078353A1 (en) 2012-11-14 2013-11-13 Compositions and methods for the treatment of ectodermal dysplasia

Publications (1)

Publication Number Publication Date
BR112015011099A2 true BR112015011099A2 (pt) 2017-08-22

Family

ID=50731641

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011099A BR112015011099A2 (pt) 2012-11-14 2013-11-13 Composições e métodos para o tratamento de diplasia ectodérmica

Country Status (14)

Country Link
US (1) US20160272694A1 (pt)
EP (1) EP2920318A4 (pt)
JP (1) JP2015536344A (pt)
KR (1) KR20150099720A (pt)
AR (1) AR093476A1 (pt)
AU (1) AU2013344973B2 (pt)
BR (1) BR112015011099A2 (pt)
CA (1) CA2891386A1 (pt)
IL (1) IL238602A0 (pt)
MX (1) MX2015005993A (pt)
RU (1) RU2015117995A (pt)
SG (1) SG11201503777YA (pt)
TW (1) TW201438730A (pt)
WO (1) WO2014078353A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300013B2 (en) 2013-10-22 2019-05-28 Espoirxlhed Sàrl Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias
JP2020154178A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
JP2020154180A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
JP2020154179A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
CN114145452B (zh) * 2021-12-10 2022-11-01 青岛圣桐营养食品有限公司 特殊医学用途全营养配方食品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US7736657B2 (en) * 2002-02-10 2010-06-15 Apoxis S.A. Fusion constructs containing active sections on TNF ligands
EP3366701B1 (en) * 2011-05-13 2019-07-03 EspoirXLHED Sàrl Compositions and methods for the alteration of xlhed phenotypes

Also Published As

Publication number Publication date
TW201438730A (zh) 2014-10-16
CA2891386A1 (en) 2014-05-22
US20160272694A1 (en) 2016-09-22
AU2013344973B2 (en) 2016-10-06
MX2015005993A (es) 2015-12-09
WO2014078353A1 (en) 2014-05-22
AU2013344973A1 (en) 2015-05-14
KR20150099720A (ko) 2015-09-01
AR093476A1 (es) 2015-06-10
RU2015117995A (ru) 2017-01-10
EP2920318A1 (en) 2015-09-23
EP2920318A4 (en) 2016-04-13
JP2015536344A (ja) 2015-12-21
IL238602A0 (en) 2015-06-30
SG11201503777YA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
UY36408A (es) Derivados de pirido benzodiazepina sustituidos y su utilización
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
PH12015501538A1 (en) Topical ocular analgesic agents
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
BR112014033118A8 (pt) Combinações farmacêuticas de um inibidor de cdk4/6 e um inibidor de b-raf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]